
- /
- Supported exchanges
- / US
- / CRNX.NASDAQ
Crinetics Pharmaceuticals Inc (CRNX NASDAQ) stock market data APIs
Crinetics Pharmaceuticals Inc Financial Data Overview
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and cushing's disease; and CRN09682, a nonpeptide drug conjugate for SST2 positive solid tumors. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease; SST3 Agonist program for the treatment for autosomal dominant polycystic kidney disease; and Radionetics for multiple solid-tumors, as well as Oral GLP-1 and Oral GIP nonpeptides for the treatment of obesity. The company has an agreement with Sanwa Kagaku Kenkyusho Co., Ltd to develop and commercialize Paltusotine in Japan, and Cellular Longevity, Inc. to develop and commercialize CRN01941, a somatostatin receptor type 2 agonist. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Crinetics Pharmaceuticals Inc data using free add-ons & libraries
Get Crinetics Pharmaceuticals Inc Fundamental Data
Crinetics Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 760 K
- EBITDA: -373 494 016
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-07
- EPS/Forecast: -0.9523
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Crinetics Pharmaceuticals Inc News

Crinetics Pharmaceuticals' SWOT analysis: promising pipeline drives stock outlook
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), a biopharmaceutical company specializing in oral therapies for endocrine diseases, is garnering attention from investors and analysts alike. With a marke...


Crinetics stock maintains Buy rating at Jones Trading on positive ENDO'25 data
Investing.com - Jones Trading has reiterated a Buy rating and $71.00 price target on Crinetics (NASDAQ:CRNX), currently trading at $32.80, following the company’s presentations at ENDO’25. Accordi...

CRNX March 2026 Options Begin Trading
Investors in Crinetics Pharmaceuticals Inc (Symbol: CRNX) saw new options become available today, for the March 2026 expiration. One of the key inputs that goes into the price an option buyer is will...

Crinetics Pharmaceuticals (CRNX) Gets Initiated With a Hold Rating at Goldman Sachs
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is one of the best oversold NASDAQ stocks to buy now. In a report released on July 10, Richard Law CFA from Goldman Sachs initiated coverage of Crinetics ...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.